Abzu is the best in class in silico disease understanding and drug design company. Since its founding in 2018, Abzu’s proprietary explainable AI, the QLattice®, has been the cornerstone to their cutting-edge approach. Abzu is a preferred partner for pharma, biotech, and research institutions, transforming data into insights and accelerating R&D. Abzu has offices in Copenhagen and Barcelona, and has raised €13.3M in total funding to date. Abzu has been mentioned in Gartner® research, from Market Guides for AI Trust, Risk, and Security Management to Cool Vendor™, and is the winner of several awards, including the 2023 “Best HealthTech” Nordics Award at the Nordic Startup Awards.
| Website | http://abzu.ai |
| Revenue | $5.1 million |
| Employees | 19 (13 on RocketReach) |
| Founded | 2018 |
| Technologies |
JavaScript
,
HTML
,
PHP
+26 more
(view full list)
|
| Industry | Biotechnology Research, Artificial Intelligence, Data, Deep Learning, Machine Learning, AI Platform, Cell Based Model, Predictive Problems, Artificial General Intelligence, Meta Learning, AGI |
| Keywords | Drug Discovery, Drug Design, Ai Drug Discovery, Artificial Intelligence, Disease Modeling, Explainable Ai, Machine Learning, Precision Medicine, Computational Biology, Predictive Modeling, Molecular Modeling, In Silico, Biotechnology, Bioinformatics, Therapeutics, Pharmaceutical, Genomics, Proteomics, Deep Learning |
| Competitors | Amazon, Microsoft, IBM, Salesforce, NVIDIA, OpenAI, C3 AI, DataRobot, H2O.ai, AI Community +47 more (view full list) |
Looking for a particular Abzu employee's phone or email?
The Abzu annual revenue was $5.1 million in 2026.
Jonas Wilstrup is the Chief Operating and Financial Officer of Abzu.
13 people are employed at Abzu.